Neurocrine Analysis Sets 6-Point EQ-VAS Benchmark for Meaningful Health Improvement in Tardive Dyskinesia

Bitget2026/10/26 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Neurocrine Biosciences announced a new analysis establishing a benchmark for clinically meaningful improvement in patient-reported overall health with Ingrezza for tardive dyskinesia.
The benchmark supports previously reported KINECT-PRO findings showing meaningful improvements in overall health, daily functioning and involuntary movements.
Findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, Oct. 26-29 in San Diego.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260830PR_NEWS_USPR_____LA79273) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Neurocrine Analysis Sets 6-Point EQ-VAS Benchmark for Meaningful Health Improvement in Tardive Dyskinesia

You may also like

Crypto prices